Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure
A Multi-center, Randomized, Double-blind , Placebo Parallel Controlled, Standard Therapy Based Phase III Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure
Sponsor: Zensun Sci. & Tech. Co., Ltd.
Terminated
The same protocol has been launched in United States.
Other terminated trials from Zensun Sci. & Tech. Co., Ltd.
- Chronic Heart Failure · Phase PHASE3 · Aug 2017
- Chronic Heart Failure · Phase PHASE3 · Aug 2012
- Chronic Heart Failure · Phase PHASE3 · Jun 2012
- Chronic Systolic Heart Failure · Phase PHASE3 · Jun 2012
More terminations from Zensun Sci. & Tech. Co., Ltd.
Other Chronic Heart Failure trials with similar outcome
Listed as NCT01214096, this PHASE3 trial focuses on Chronic Heart Failure and remains terminated or withdrawn. Sponsored by Zensun Sci. & Tech. Co., Ltd., it has been updated 6 times since 2010, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Jan 2018 — Jun 2018 [monthly]
Terminated PHASE3
Status: Suspended → Terminated
▶ Show 1 earlier version
-
Jan 2017 — Jan 2018 [monthly]
Suspended PHASE3
First recorded
Jul 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Zensun Sci. & Tech. Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .